Abstract: A toilet management system includes a toilet bowl device installed in a toilet room, a management device configured to manage a use situation of the toilet bowl device, and a communication device configured to transmit use situation information related to the use situation of the toilet bowl device to the management device. The management device includes an acquirer configured to acquire the use situation information from the communication device, and an abnormality detector configured to detect an abnormality of the toilet bowl device or a facility or equipment installed inside or around the toilet room when the use situation information acquired by the acquirer matches a predetermined condition.

Abstract: A composite sintered body includes a base material that includes ceramic as a main component, and an electrode arranged inside the base material or on a surface of the base material. The electrode contains W and ZrO2.

Abstract: A learning system which is capable of easily collecting data of affected parts having completely recovered, as training data. When it is determined that an affected part has completely recovered based on affected-part image data generated by shooting the affected part, image data accompanied with the same affected part ID as that of the affected-part image data is identified from among image data set stored in a storage device of the learning system. The actual number of days to a complete recovery of the affected part is calculated from shooting dates of the identified image data and the affected-part image data, and is added to the affected-part image data. The affected-part image data accompanied with the actual number of days to the complete recovery is used as training data to create a trained model that predicts the number of days to a complete recovery of the affected part.

Abstract: An electronic device comprising: a line-of-sight detection unit configured to receive line-of-sight input from a user and detect a viewed position of the user; an acquisition unit configured to acquire first distance information that corresponds to a distance to an eye of the user; and a control unit configured to 1) set determination time based on the first distance information, and 2) determine that gaze has occurred, in a case where determination is made that the viewed position does not continuously change longer than the determination time.

Abstract: An electronic device comprising: a line-of-sight detection unit configured to receive line-of-sight input from a user and detect a viewed position of the user; an acquisition unit configured to acquire first distance information that corresponds to a distance to an eye of the user; and a control unit configured to 1) set determination time based on the first distance information, and 2) determine that gaze has occurred, in a case where determination is made that the viewed position does not continuously change longer than the determination time.

Abstract: The present invention provides a method for producing a difluoromethylene compound and an intermediate thereof, which are useful in the field of pharmaceuticals. Specifically provided is a method for producing a difluoromethylene compound, including a step of allowing a compound represented by formula (6): [wherein L1 represents a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a hydroxy lower alkyl group; R1 represents a lower alkyl group, a halogen atom, a halo-lower alkyl group, a cycloalkyl group, a cyano group, or a hydroxy lower alkyl group; and W represents a nitrogen atom or a methine group] to react with a compound represented by formula (7): [wherein R2 represents a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkenyl group, or an aralkyl group; and R3 represents a chlorine atom, a bromine atom, or an iodine atom].

Abstract: The present invention provides a method for producing a difluoromethylene compound and an intermediate thereof, which are useful in the field of pharmaceuticals. Specifically provided is a method for producing a difluoromethylene compound, including a step of allowing a compound represented by formula (6): [wherein L1 represents a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a hydroxy lower alkyl group; R1 represents a lower alkyl group, a halogen atom, a halo-lower alkyl group, a cycloalkyl group, a cyano group, or a hydroxy lower alkyl group; and W represents a nitrogen atom or a methine group] to react with a compound represented by formula (7): [wherein R2 represents a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkenyl group, or an aralkyl group; and R3 represents a chlorine atom, a bromine atom, or an iodine atom].

Abstract: An image pickup apparatus which is capable of shortening a time period required for photometric measurement and obtaining an accurate photometric measurement value when there has been a shift from a photometric measurement operation using an image pickup device to a photometric measurement operation using a linear photometric sensor. When there has been no shift from a photometric measurement operation by the image pickup device to a photometric measurement operation by the photometric sensor, the photometric sensor performs a first photometric measurement operation for a plurality of times, and when there has been a shift from a photometric measurement operation by the image pickup device to a photometric measurement operation by the photometric sensor, a second photometric measurement operation is performed for a smaller number of times than that of the first photometric measurement operation according to a result of photometric measurement performed by the image pickup device.

Abstract: A compound having an URAT1 inhibitory activity, and an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

Abstract: An image capturing apparatus comprises an image capturing unit, a calculation unit configured to calculate light amount variation characteristics of light from an object, a photometric value determination unit configured to determine a photometry value used for determination of an exposure condition based on the light amount variation characteristics calculated by the calculation unit, and an exposure condition determination unit configured to determine an exposure condition when performing exposure of the image capturing unit at a timing set based on the light amount variation characteristics calculated by the calculation unit, based on the photometry value determined by the photometric value determination unit.

Abstract: A compound having an URAT1 inhibitory activity, and an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

Abstract: An image pickup apparatus which is capable of shortening a time period required for photometric measurement and obtaining an accurate photometric measurement value when there has been a shift from a photometric measurement operation using an image pickup device to a photometric measurement operation using a linear photometric sensor. When there has been no shift from a photometric measurement operation by the image pickup device to a photometric measurement operation by the photometric sensor, the photometric sensor performs a first photometric measurement operation for a plurality of times, and when there has been a shift from a photometric measurement operation by the image pickup device to a photometric measurement operation by the photometric sensor, a second photometric measurement operation is performed for a smaller number of times than that of the first photometric measurement operation according to a result of photometric measurement performed by the image pickup device.

Abstract: The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

Abstract: The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.

Abstract: The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.

Abstract: The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

Abstract: An image capturing apparatus comprises an image capturing unit, a calculation unit configured to calculate light amount variation characteristics of light from an object, a photometric value determination unit configured to determine a photometry value used for determination of an exposure condition based on the light amount variation characteristics calculated by the calculation unit, and an exposure condition determination unit configured to determine an exposure condition when performing exposure of the image capturing unit at a timing set based on the light amount variation characteristics calculated by the calculation unit, based on the photometry value determined by the photometric value determination unit.

Abstract: The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.

Abstract: The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.

Abstract: The present invention relates to a compound of general formula I: wherein: n1 and n2 are the same or different, and are 0 or 1; R is aryl, heteroaryl, etc.; Re is hydrogen atom or lower alkyl; two groups selected from four groups consisting of (i) either one of Ra1 and Ra1?, (ii) either one of Ra2 and Ra2?, (iii) either one of Rb1 and Rb1?, and (iv) either one of Rb2 and Rb2?, are combined to form —(CH2)n— where n is 1, 2 or 3; and among Ra1, Ra1?, Ra2, Ra2?, Rb1, Rb1?, Rb2 and Rb2?, the groups which do not form —(CH2)n— are each independently hydrogen atom, etc.; X1, X2, X3 and X4 are each independently CH, N, etc.; Y1, Y2, Y3 and Y4 are the same or different and are CH or N, etc.; W is a 5-membered aromatic heterocyclic group, or a pharmaceutically acceptable salt or ester thereof.